Phase 2 Study of Tapentadol Prolonged Release in Cancer Pain Participants
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics (how the
drug is absorbed in the body, distributed within the body, and how it is removed from the
body over time; explores what the body does to the drug) of tapentadol prolonged release
(JNS024PR, PR) in participants with moderate to severe cancer (abnormal tissue that grows and
spreads in the body until it kills) pain.